Sickle Cell Disease Treatment Market

Global sickle cell diseases treatment market: Sickle cell diseases are the type of blood disorders which are genetically inherited. Anemia is a drastic reduction in total RBC count. It is also defined as the inability of carrying the appropriate amounts of oxygen by blood. Sickle-cell anemia is the common type of SCD in which sickle-shaped cell is formed. Generally, sickle cell disease starts taking shape at the early age i.e., within a year after birth which leads to several health issues like attacks of pain which are also called as the sickle-cell crisis, limbs swelling, bacterial infections etc. Chronic pain can be developed along with the age. Sickle-cell diseases arise when an individual inherited by abnormal copies of Hg gene from each parent.

The sickle cell diseases treatment market is driven by the increasing prevalence of sickle cell anemia in the developed, developing as well as underdeveloped countries. In addition to this unmet needs are highly available, a rise in product pipelines for the treatment of SCD is anticipated to pose great demand for the market. Sickle cell disease treatment market is propelled by rising support by the regulatory bodies and government in the form of investments, fast-track approvals for the discovery of newer treatments. Sickle cell anemia treatment market is restrained by slow adoption of treatments due to the high cost, the absence of a permanent cure for this disease and complications associated with treatment.

Free sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/sickle-cell-diseases-treatment-market/#ulp-4H8Z4LpNMLEuOnnx

On the basis of disease type, the global Sickle cell diseases treatment market treatment is divided as-

1. Disease type
• Sickle Beta Thalassemia
• Sickle Hemoglobin C Disease
• Sickle Cell Anemia
• Others

2. Therapy
• Bone Marrow Transplant
• Blood Transfusion
• Gene Therapy

3. Drug class
• Antibiotics
• Analgesics
• Antimetabolite (Hydroxyurea)
• Others

4. End-users
Hospitals, retail pharmacies and others.

Free TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/sickle-cell-diseases-treatment-market/#ulp-c654SbFYO64MsOhu

Based on the geographical regions, the global Sickle cell diseases treatment market is segmented into Latin America, Europe, North America, the Middle East and Africa, and the Asia Pacific. North America dominates the sickle cell anemia treatment market due to the increase in activities in R&D, high accessibility of developed healthcare infrastructure and high reimbursement policies are attributing for the growth of the SCD treatment market in the region. Owing to the high prevalence rate of disease in the Asia Pacific and African regions is favoring the growth of SCD treatment market. Asia-Pacific is one of the highly anticipated growing markets due to the funding of the various industry players for stem cell research.

Some of the sickle cell disease treatment providers are Biogen (U.S.), Gamida Cell (Israel), Genetix Pharmaceuticals Inc. (U.S.), Sangamo Biosciences (U.S.), Alnylam Pharmaceuticals, Inc. (U.S.), Acceleron Pharma (U.S.), Global Blood Therapeutics Inc. (U.S.), Emmaus Medical, Inc. (U.S.), Novartis AG (Switzerland) and Bristol-Myers Squibb Company (U.S.). In 2017, Emmaus Medical Inc. Endari (L-glutamine oral powder) received USFDA approval to treat the patients with age of five years and older having sickle cell disease. While in 2016 Novartis AG acquired Selexys Pharmaceuticals in order to expand product offerings related to blood disorders and diseases.

Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/sickle-cell-diseases-treatment-market/#ulp-14mlyhjMGhVjZqa3


As per Centre for Disease Control and Prevention, in 2016, about 100,000 individuals in U.S. were affected by the sickle cell diseases. According to ethnicity, Black or the African Americans are commonly more susceptible to sickle cell diseases. One in thirteen babies who belongs to the black race are born with SCD’s. Researchers have moved ahead to treat SCD by antibiotics to genome level. Researchers from the Stanford School of Medicine corrected the genes successfully which are carrying a gene for SCD and transplanted them with the healthy cells. With the help of Clustered Regularly Interspaced Short Palindromic Repeat technique (CRISPR), researchers have replaced the SCD cell genes with one which doesn’t carry those genes. In 2016, Infosys had donated USD 1.11 million for the stem cell research to develop gene therapies for the disorders like Hemophilia and sickle cell disease.

Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/sickle-cell-diseases-treatment-market/

About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US):+1-866-598-1553
Website @https://www.precisionbusinessinsights.com